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Abstract
Background: Combination therapy is frequently used to treat patients with pulmonary hypertension but few studies
have compared treatment regimens. This study examined the long-term effect of different combination regimens of
inhaled iloprost and oral sildenafil on survival and disease progression.
Methods: This was a retrospective study of patients in the Giessen Pulmonary Hypertension Registry who received
iloprost monotherapy followed by addition of sildenafil (iloprost/sildenafil), sildenafil monotherapy followed by addition
of iloprost (sildenafil/iloprost), or upfront combination therapy (iloprost + sildenafil). The primary outcome was
transplant-free survival (Kaplan–Meier analysis). When available, haemodynamic parameters and 6-minute-walk
distance were evaluated.
Results: Overall, 148 patients were included. Baseline characteristics were similar across treatment groups; however,
the iloprost + sildenafil cohort had higher mean pulmonary vascular resistance and pulmonary arterial pressure than the
others. Transplant-free survival differed significantly between groups (P = 0.007, log-rank test). Cumulative transplant-free
survival was highest for patients who received iloprost/sildenafil (1 year survival: iloprost/sildenafil, 95.1 %;
sildenafil/iloprost, 91.8 %; iloprost + sildenafil, 62.9 %); this group also remained on monotherapy significantly
longer than the sildenafil/iloprost group (median 17.0 months vs 7.0 months, respectively; P = 0.004). Compared
with pre-treatment values, mean 6-minute-walk distance increased significantly for all groups 3 months after
beginning combination therapy.
Conclusions: In this observational study of patients with pulmonary hypertension receiving combination therapy
with iloprost and sildenafil, cumulative transplant-free survival was highest in those who received iloprost monotherapy
initially. However, owing to the size and retrospective design of this study, further research is needed before making
firm treatment recommendations.
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Background
Pulmonary hypertension (PH) is a life-threatening dis-
order with a variety of aetiologies [1]. Because PH is a
multifactorial condition, monotherapy focused on a single
pathological pathway may be insufficient to halt disease
progression. By acting on two or more biological path-
ways, combination therapies have the potential for
increased efficacy over monotherapies. In patients with
PH, two main approaches for combining treatments may
be followed, with therapies introduced sequentially or
concomitantly as ‘upfront’ combination therapy. Mono-
therapy is normally used initially, with additional therapy
introduced if clinical deterioration occurs. Less frequently,
combination treatment is used as first-line therapy to
exploit the ‘hit hard and early’ model, which aims to use
early and aggressive treatment to halt disease progression
[2]. This approach is also recommended in international
guidelines for patients with PH, for those with severe
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disease (defined as class IV according to the World Health
Organisation functional class system) [3].
Treatment guidelines also suggest combining estab-
lished pharmacotherapies for patients with PH who
do not respond adequately to monotherapy, but do
not recommend particular combinations or regimens
[3]. During a 3 year study employing pre-defined
treatment goals to guide therapeutic decisions, com-
bination therapy was eventually required by almost
half of patients initially prescribed monotherapy [4].
Several studies have examined the combination of the
prostanoid iloprost and the phosphodiesterase type 5
(PDE-5) inhibitor sildenafil in the treatment of
patients with PH. In acute haemodynamic testing,
combining these drugs led to a greater reduction in
pulmonary vascular resistance (PVR) than each agent
alone [5]. Furthermore, patients with pulmonary
arterial hypertension (PAH) showed improved exercise
capacity and haemodynamics when given sildenafil as
an add-on to existing iloprost therapy [6]. Random-
ized controlled trials directly comparing the efficacy
of iloprost and sildenafil have not been undertaken,
although a meta-analysis found no significant differ-
ence in efficacy between these therapies [7]. The aim
of this study was to examine the long-term effect of
different combination regimens of inhaled iloprost and
oral sildenafil on the survival and disease progression of
patients with PH.
Methods
Study design
This was an observational study [8] of patients in the
Giessen Pulmonary Hypertension Registry, a single-centre
registry including more than 2500 patients with newly
diagnosed disease. The registry started in 1993. For this
study, the patients who met the eligibility criteria had been
enrolled from 1993 to 2013. Adult patients who received a
combination of inhaled iloprost and oral sildenafil were
eligible for inclusion. Patients who received intravenous
iloprost or sildenafil, or who had begun treatment with
therapies other than iloprost or sildenafil, were excluded.
Each patient gave informed consent to participate.
The study was approved by the University of Giessen
Institutional Review Board (reference number 266/11)
and followed the principles of the Declaration of
Helsinki.
Three treatment regimens were studied: iloprost mono-
therapy followed by addition of sildenafil (iloprost/sildena-
fil); sildenafil monotherapy followed by addition of iloprost
(sildenafil/iloprost); and upfront combination therapy of
iloprost and sildenafil (iloprost + sildenafil). No pre-defined
protocol was followed; treatment and doses were tailored
to the individual patient’s needs and optimized by dose-
titration.
Outcome measures
The primary outcome measure was transplant-free
survival, as calculated by Kaplan–Meier analysis. As this
was a retrospective study of patient records, complete
information could not be obtained in all cases. When
available, 6-minute-walk distance (6MWD), New York
Heart Association (NYHA) functional class, pulmonary
arterial pressure (PAP), PVR, and cardiac output were
analysed. Changes were compared using intra-individual
paired analysis (i.e. including only patients with both
baseline and post-treatment data available). Values were
determined pre-treatment (baseline), 3 months after
monotherapy initiation, before combination therapy initi-
ation (post-monotherapy baseline), and 3 months after
combination therapy initiation. Patients lost to follow-up
were classified as having withdrawn alive on the date of
last contact.
Statistical methods
Data are presented as mean (standard deviation) or median
(interquartile range), as applicable. The log-rank test was
used to analyse differences in cumulative transplant-free
survival; analysis of variance was applied to test for differ-
ences between groups; and the paired t-test (two-tailed)
was used to examine changes in response to therapy. Cox
regression, defining iloprost as the reference, was applied
to control for possible confounders in survival analysis, cor-
recting for NYHA functional class, 6MWD, and cardiac
output. The Kruskal–Wallis test was performed to test for
differences in parameters with skewed distributions.
Results
Baseline characteristics
In total, out of 685 patients assessed, 148 patients were
eligible for the study. Similar numbers of patients initially
received iloprost or sildenafil monotherapy (61 patients
and 63 patients, respectively), and 24 received upfront
combination therapy (Table 1). In the iloprost/sildenafil
group, idiopathic PAH and PAH associated with other
conditions (Dana Point classification 1.4) [1] were the
most frequent aetiologies (35.0 % and 33.3 %, respectively).
Similarly, patients treated with sildenafil/iloprost were
mainly those with idiopathic PAH or PAH associated with
other conditions (25.0 % and 43.3 %, respectively). The
most common classification for patients who received up-
front combination therapy was idiopathic PAH (47.8 %).
Baseline characteristics were broadly similar in the treat-
ment groups (Table 1). The mean age at diagnosis of the
sildenafil/iloprost group was significantly higher than that
of the iloprost + sildenafil group (53.0 years vs 43.3 years,
respectively; P = 0.029); otherwise, there were no signifi-
cant differences between the mean ages of the groups.
Patients who initially received iloprost monotherapy
were admitted to the study centre earlier (median date
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November 2000) than those beginning sildenafil mono-
therapy or combination therapy (median dates April
and August 2003, respectively; P < 0.001). The mean
baseline 6MWD was lower for patients who received
upfront combination therapy than for the other groups
(Table 1), but not significantly so (P = 0.227).
Patients who received upfront combination therapy
had significantly higher mean PAP than patients ini-
tially treated with iloprost or sildenafil monotherapy
(P < 0.001 [Table 1]). Between treatment groups,
however, there was no significant difference in cardiac
output (P = 0.264). Patients treated with upfront
combination therapy had higher mean PVR than
those who started on iloprost or sildenafil monother-
apy (P < 0.001). Data for exercise capacity and haemo-
dynamic parameters were not available for all patients.
The proportions of patients who went on to receive
additional therapy with an endothelin receptor antagonist,
an intravenous prostanoid or both were 48.6 %, 5.4 %, and
13.5 %, respectively. Patients were followed up for a mean
of 60.9 months.
Duration of monotherapy treatment
Patients initially treated with iloprost remained on mono-
therapy significantly longer than those starting with silden-
afil (P = 0.004; Fig. 1). Median time on monotherapy was
17.0 months (95 % confidence interval: 10.4–23.6 months)
with iloprost and 7.0 months (95 % confidence interval:
4.2–9.8 months) with sildenafil.
Cumulative transplant-free survival
In total, eight patients were lost to follow-up: three in the
iloprost/sildenafil group, one in the sildenafil/iloprost
group, and four in the iloprost + sildenafil group. There
was a significant difference in transplant-free survival
Table 1 Baseline characteristics of patients who were eligible for the observational study
Characteristic Treatment regimena
Iloprost/sildenafil Sildenafil/iloprost Iloprost + sildenafil
n = 61 n = 63 n = 24
Female sex, % 65.0 66.7 78.3
[n = 60] [n = 60] [n = 23]
Mean age at diagnosis, years (SD) 48.7 (14.9) 53.0 (15.2) 43.3 (17.1)
Classification of PH, n (%)
Idiopathic PAH 21 (35.0) 15 (25.0) 11 (47.8)
PAH associated with other conditionsb 20 (33.3) 26 (43.3) 6 (26.1)
Associated with lung diseases 4 (6.7) 9 (15.0) 1 (4.3)
CTEPH 14 (23.3) 10 (16.7) 3 (13.0)
Miscellaneous 1 (1.7) 0 (0.0) 2 (8.7)
[n = 60] [n = 60] [n = 23]
NYHA functional class, n (%)
II 3 (10.3) 4 (8.5) 0 (0)
III 13 (44.8) 18 (38.3) 5 (38.5)
IV 13 (44.8) 25 (53.2) 8 (61.5)
[n = 29] [n = 47] [n = 13]
Mean PAP, mmHg (95% CI) 55 (51–58) 57 (53–61) 73 (65–82)
[n = 50] [n = 51] [n = 21]
Mean cardiac output, L/min (95% CI) 3.4 (3.1–3.7) 3.6 (3.3–3.9) 3.1 (2.5–3.7)
[n = 49] [n = 51] [n = 21]
Mean PVR, dyn.s.cm−5 (95% CI) 1287 (1134–1440) 1143 (1016–1270) 1824 (1538–2109)
[n = 49] [n = 51] [n = 21]
Mean 6MWD, m (95% CI) 276 (232–319) 281 (245–317) 222 (179–265)
[n = 38] [n = 48] [n = 16]
6MWD 6-minute-walk distance; CHD congenital heart disease; CI confidence interval; CTD connective tissue disease; CTEPH chronic thromboembolic pulmonary
hypertension; ILD interstitial lung disease; NYHA New York Heart Association; PAH pulmonary arterial hypertension; PAP pulmonary arterial pressure; PVR
pulmonary vascular resistance; SD standard deviation
aThe treatment regimens were: iloprost/sildenafil (iloprost followed by addition of sildenafil), sildenafil/iloprost (sildenafil followed by addition of iloprost), or
iloprost + sildenafil (combined iloprost and sildenafil as upfront therapy); bDana Point classification 1.4 [1]
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among groups (P = 0.007, log-rank test; Fig. 2a). Cumula-
tive transplant-free survival was highest in the iloprost/sil-
denafil group and lowest for those who received upfront
combination therapy. In the iloprost/sildenafil group,
survival rates were 95.1 % at 1 year, 81.8 % at 3 years, and
66.4 % at 5 years. In the sildenafil/iloprost group, survival
rates were 91.8 % at 1 year, 68.1 % at 3 years, and 54.5 % at
5 years. Survival rates were 62.9 % at 1 year, 57.7 % at
3 years, and 50.5 % at 5 years for patients who received
upfront combination therapy.
After Cox regression analysis, cumulative transplant-free
survival was significantly higher in the iloprost/sildenafil
group than in the sildenafil/iloprost group (P = 0.035;
Fig. 2b). Survival was also higher for patients treated with
iloprost/sildenafil than for those treated with upfront com-
bination therapy, but this difference was not statistically
significant (P = 0.120).
Cumulative transplant-free survival based on the aetiology
of pulmonary hypertension
For patients with PAH initially treated with iloprost or
sildenafil, cumulative transplant-free survival was analysed
by PH classification (Additional file 1: Figure S1). For all
groups assessed (PAH associated with collagen-vascular
disease, idiopathic PAH, and PAH associated with
systemic-to-pulmonary shunt), survival was higher in the
iloprost/sildenafil group than in the sildenafil/iloprost
group. No statistical analyses were conducted because the
number of patients in these sub-analyses was small.
Change in functional class
The iloprost/sildenafil group had a lower proportion of
patients in NYHA functional class IV at pre-treatment
baseline than the sildenafil/iloprost group (Fig. 3). The
proportion of patients in NYHA functional class IV
showed a more pronounced decrease with sildenafil than
with iloprost. The lowest proportion of patients in
NYHA functional class IV was observed after addition
of the second therapy in both groups.
Fig. 1 Kaplan–Meier plot of proportions of patients remaining on
iloprost or sildenafil monotherapy over time
Fig. 2 Transplant-free survival. (a) Kaplan–Meier plot of cumulative
transplant-free survival and (b) Cox regression estimate of transplant-free
survival after correction for possible confounders (New York Heart
Association functional class, 6-minute-walk distance, and cardiac output).
Patients were treated sequentially with iloprost and sildenafil (either
iloprost followed by addition of sildenafil [iloprost/sildenafil] or sildenafil
followed by addition of iloprost [sildenafil/iloprost]), or with upfront
combination therapy (iloprost + sildenafil)
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Change in mean pulmonary arterial pressure
There was no significant change in mean PAP measured
3 months after therapy initiation from pre-treatment
baseline for patients initially treated with iloprost
(Fig. 4a). Following combination therapy, mean PAP was
significantly reduced compared with post-monotherapy
baseline (P = 0.037). However, there was no significant
change in mean PAP after 3 months of combination
therapy compared with pre-treatment baseline.
Mean PAP was significantly reduced from a pre-
treatment baseline of 57 mmHg to 50 mmHg for patients
who received sildenafil monotherapy (P = 0.001; Fig. 4b).
However, mean PAP was unchanged 3 months after
beginning combination therapy compared with post-
monotherapy baseline. Compared with pre-treatment
baseline, there was no significant change in mean PAP
after combination therapy (P = 0.148).
For patients who began initial combination therapy,
mean PAP was significantly reduced from a pre-treatment
value of 79 mmHg to 69 mmHg after 3 months of
treatment (P = 0.018; Fig. 4c).
Change in mean cardiac output
Mean cardiac output was unchanged 3 months after begin-
ning iloprost therapy compared with pre-treatment values
(Fig. 4d). However, after combination therapy, mean cardiac
output was increased compared with post-monotherapy
baseline, from 2.9 L/min to 3.4 L/min (P = 0.001). There
was no significant difference between mean cardiac output
pre-treatment and following combination therapy.
For patients initially treated with sildenafil, mean car-
diac output increased from 3.5 L/min at pre-treatment
baseline to 4.1 L/min 3 months after beginning treat-
ment (P = 0.001; Fig. 4e). Following iloprost addition, there
was no significant change in mean cardiac output com-
pared with post-monotherapy or pre-treatment baselines.
Similarly, for patients treated with combination therapy
initially, there was no significant change in mean cardiac
output compared with pre-treatment baseline (Fig. 4f).
Change in mean pulmonary vascular resistance
After 3 months of iloprost monotherapy, there was no sig-
nificant change in mean PVR compared with pre-
treatment baseline (Fig. 4g). However, mean PVR was sig-
nificantly reduced 3 months after initiating combination
treatment compared with post-monotherapy baseline,
from 1455 dyn.s.cm−5 to 1143 dyn.s.cm−5 (P = 0.006). A
significant reduction in mean PVR was also seen following
combination therapy when compared with pre-treatment
values (P = 0.006).
Mean PVR was significantly reduced from a pre-
treatment baseline of 1161 dyn.s.cm−5 to 909 dyn.s.cm−5
3 months after beginning sildenafil monotherapy (P < 0.001;
Fig. 4h). However, 3 months after beginning combination
therapy there was no change in mean PVR compared with
post-monotherapy or pre-treatment baselines.
For patients treated initially with combination therapy,
there was no significant change in mean PVR compared
with pre-treatment baseline (Fig. 4i).
Change in 6-minute-walk distance
Compared with pre-treatment values, patients who received
initial iloprost monotherapy showed significantly increased
mean 6MWD, from 283 m to 346 m (P < 0.001; Fig. 4j).
Exercise capacity was also improved following add-on sil-
denafil therapy: compared with post-monotherapy baseline,
mean 6MWD increased from 345 m to 374 m (P = 0.01).
Mean 6MWD increased from 283 m at pre-treatment
Fig. 3 New York Heart Association (NYHA) functional class over the
study. a Patients received iloprost followed by addition of sildenafil.
b Patients received sildenafil followed by addition of iloprost
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baseline to 374 m 3 months after beginning combination
therapy (P < 0.001).
For patients who received initial sildenafil monotherapy,
mean 6MWD increased from 278 m at pre-treatment
baseline to 307 m 3 months after beginning treatment
(P = 0.036; Fig. 4k). Subsequently, patients treated with
add-on iloprost therapy showed increased exercise cap-
acity compared with post-monotherapy baseline, with
mean 6MWD increased from 303 m to 328 m (P = 0.002).
Compared with pre-treatment values, mean 6MWD
increased from 280 m to 312 m for patients treated with
combination therapy (P = 0.038).
6MWD increased from 213 m to 305 m for patients
treated with upfront combination therapy compared
with pre-treatment baseline (P = 0.001; Fig. 4l).
Discussion
In the treatment of patients with PH, clinical studies have
evaluated combinations of major pharmacological classes
of medical therapies, i.e. endothelin receptor antagonists
Fig. 4 Changes in haemodynamic parameters and 6-minute-walk distance over the study (intra-individual responses). (a–c) Pulmonary arterial
pressure (PAP), (d–f) cardiac output, (g–i) pulmonary vascular resistance (PVR), and (j–l) 6-minute-walk distance (6MWD). Data are presented as
means ± 95 % confidence interval. Patients were treated with iloprost followed by addition of sildenafil (iloprost/sildenafil), sildenafil followed by
addition of iloprost (sildenafil/iloprost), or upfront combination therapy with iloprost and sildenafil (iloprost + sildenafil). Values are shown pre-treatment
(baseline), 3 months after therapy initiation (monotherapy), before combination therapy (post-monotherapy baseline), and 3 months after
starting combination therapy (combined therapy). *P < 0.05; **P < 0.01; ***P < 0.001. Statistical analysis was conducted using the paired
sample t-test (two-tailed)
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and prostanoids [9–12], endothelin receptor antagonists
and PDE-5 inhibitors [13, 14], and prostanoids and PDE-5
inhibitors [5, 6, 15–19]. However, only one study, of
administration of the prostanoid treprostinil for up to
2 years in patients receiving oral background PAH ther-
apy, examined long-term outcomes (survival and clinical
worsening [defined as addition of a new PAH therapy,
discontinuation due to disease progression, or death])
[20]. A meta-analysis of randomized controlled studies in
patients with PAH found that, compared with monother-
apy, combination therapy significantly reduced clinical
deterioration, increased 6MWD, and improved haemo-
dynamics [21]. However, no significant difference in
mortality was observed between patients treated with
monotherapy and those receiving combination therapy.
Iloprost and sildenafil act via different pathways (stimu-
lating cyclic adenosine monophosphate [cAMP] production
and preventing cyclic guanosine monophosphate [cGMP]
breakdown, respectively), but there is evidence of cross-talk
between these pathways. Raised cGMP levels inhibit cAMP
breakdown, and pre-treatment of erythrocytes in vitro with
PDE-5 inhibitors potentiated cAMP release in response to
treprostinil [22]. In acute haemodynamic testing in patients
with PH, the combination of sildenafil and iloprost pro-
duced a greater vasodilatory response than either agent
alone [5]. There are limited data showing the long-term
benefits of combining sildenafil and iloprost, but in a
16 week study the addition of sildenafil to long-term
treatment with the prostacyclin epoprostenol im-
proved exercise capacity and haemodynamics among
patients with PAH compared with those receiving pla-
cebo [23].
In our study, cumulative transplant-free survival was
lower for patients who received upfront combination ther-
apy than for those treated with initial monotherapy. At
1 year, the survival rate was 62.9 % for those who received
combination therapy, compared with 95.1 % and 91.8 %
for those first treated with inhaled iloprost or oral sildenafil
monotherapy, respectively. However, before therapy,
patients treated with iloprost + sildenafil had higher mean
PVR and mean PAP than those who began monotherapy.
Therefore, patients with the most severe disease had been
assigned to receive upfront combination therapy, as is
recommended in current international treatment guide-
lines for patients with PH [3]. This approach, of treating
patients with severe PAH with upfront inhaled iloprost
and oral sildenafil therapy, was taken in a separate study of
eight patients of NYHA functional class IV who were
unable to perform a 6MWD test. Following treatment, all
patients had an improvement in their functional class and
were able to complete a 6MWD test, though one patient
later underwent lung transplantation and subsequently
died [24]. Similarly, for the small number of patients for
whom measurements were recorded in our study (n = 16),
6MWD significantly increased following combination
treatment.
Among patients treated initially with monotherapy,
transplant-free survival was higher for those receiving
iloprost/sildenafil than for those treated with sildenafil/
iloprost. Patients treated with inhaled iloprost also
remained on monotherapy longer than patients beginning
oral sildenafil monotherapy. When paired recordings were
available, the benefit of sequential therapy on exercise
capacity was also observed for both drug regimens, with
6MWD significantly higher than pre-treatment values
after 3 months of combination therapy. The results from
this study suggest that when combining iloprost and sil-
denafil in a step-wise manner the optimal treatment regi-
men may be initial monotherapy with iloprost followed by
add-on sildenafil if clinical deterioration occurs.
This study has limitations. Owing to the retrospective
design, patients were not randomly assigned to each treat-
ment, as highlighted by significant differences in baseline
characteristics between the patient groups. Furthermore,
complete data were not available for functional class,
haemodynamic parameters, and exercise capacity, and
there was the potential for selection bias. Unlike treatment
with iloprost monotherapy, sildenafil monotherapy
resulted in significant improvements in haemodynamics
compared with pre-treatment values. Despite this,
transplant-free survival was shorter in patients initially
treated with sildenafil than among those who received
iloprost therapy first. This is difficult to explain, and may
reflect differences in the baseline characteristics between
these patient groups or be the result of an unrecognized
confounding factor. For these reasons, caution is needed
when comparing the effectiveness of these two monother-
apies. These outcomes also need to be viewed in the
context of treatment practices over the course of this
study, because patients who received initial iloprost
therapy were admitted to the study centre before those
first treated with sildenafil. In Europe, iloprost was
approved for the treatment of PAH 2 years before sildena-
fil. Thus, in the early years of the study, inhaled iloprost
was the only treatment available and patients may have
remained on monotherapy because no other treatment
options were available. Furthermore, this study included
patients from a period of 20 years, over which time there
were significant changes in diagnostic practices and in the
clinical management of PH, which may have influenced
the outcomes of patients.
Conclusions
In this observational study, the sequence in which pa-
tients with PH received combination therapy with ilo-
prost and sildenafil was independently associated with
transplant-free survival rate. However, owing to the
small size of the study and its retrospective design,
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further research is required to confirm the external val-
idity of the results.
Availability of Data and Materials
Data are available from the corresponding author upon
request.
Additional file
Additional file 1: Figure S1. Kaplan–Meier plots of cumulative
transplant-free survival in patients with pulmonary arterial hypertension
associated with collagen-vascular disease, idiopathic pulmonary arterial
hypertension, and pulmonary arterial hypertension associated with
systemic-to-pulmonary shunt. Data are shown for patients who were treated
with iloprost followed by addition of sildenafil (iloprost/sildenafil) or sildenafil
followed by addition of iloprost (sildenafil/iloprost). (PDF 853 kb)
Abbreviations
cAMP: Cyclic adenosine monophosphate; cGMP: Cyclic guanosine
monophosphate; 6MWD: 6-minute-walk distance; NYHA: New York Heart
Association; PAH: Pulmonary arterial hypertension; PAP: Pulmonary arterial
pressure; PDE-5: Phosphodiesterase type 5; PH: Pulmonary hypertension;
PVR: Pulmonary vascular resistance.
Competing interests
HG has received support and/or honoraria from Actelion, AstraZeneca, Bayer
Pharma AG, GlaxoSmithKline, Janssen Cilag, Lilly, Pfizer, and United Therapeutics/
OMT. RV has been an investigator and consultant for LungRx. WS has received
speaker/consultancy fees from Bayer Pharma AG and Pfizer. FG has received
research grants from Bayer Pharma AG, Ergonex, Encysive and Pfizer; honoraria
from Actelion, Bayer Pharma AG, Encysive, Novartis, and Pfizer; and has been a
paid consultant for Nycomed (Altana Pharma). HAG has received fees from
Actelion, Bayer Pharma AG, Gilead, GSK, Lilly, LungRx, Novartis, and Pfizer. The
other authors declare that they have no competing interests.
Authors’ contributions
HG contributed to the conception and design of the study, analysis of the
data, drafting the manuscript and revising the article for intellectual content.
NS contributed to the conception and design of the study, analysis of the
data, and revising the article for intellectual content. KM contributed to the
conception and design of the study, analysis of the data, and revising the
article for intellectual content. MR contributed to the conception and design
of the study, analysis of the data, and revising the article for intellectual
content. RV contributed to the conception and design of the study, analysis
of the data, and revising the article for intellectual content. WS contributed
to the conception and design of the study, analysis of the data, and revising
the article for intellectual content. FG contributed to the conception and
design of the study, analysis of the data, and revising the article for
intellectual content. H-AG contributed to the conception and design of the
study, analysis of the data, and revising the article for intellectual content. DB
contributed significantly to the design of the study and the interpretation of
the data. All the authors gave final approval of the published article and are
accountable for all aspects of the work.
Acknowledgements
Dr William Gattrell of Oxford PharmaGenesis provided medical writing
support. The authors thank Susanne Wissgott for excellent technical
assistance.
Funding
Medical writing support for this manuscript was funded by Bayer Pharma AG
at the request of the authors. Bayer Pharma AG shared scientific comments
on the draft manuscript but played no role in study design, data collection,
or analysis.
Author details
1Universities of Giessen & Marburg Lung Center, Medizinische Klinik II,
Klinikstraße 33, 35392 Giessen, Germany. 2Medical Clinic V, University of
Munich, Comprehensive Pneumology Center, Munich, Germany.
3Department of Internal Medicine, Friedberg Hospital, Friedberg, Germany.
4Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany.
5Faculty of Medicine, Imperial College London, London, UK.
Received: 4 August 2015 Accepted: 22 December 2015
References
1. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton C,
et al. Updated clinical classification of pulmonary hypertension. J Am Coll
Cardiol. 2009;54(1):S43–54.
2. Hoeper MM, Dinh-Xuan AT. Combination therapy for pulmonary arterial
hypertension: still more questions than answers. Eur Respir J. 2004;24(3):339–40.
3. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al.
Guidelines for the diagnosis and treatment of pulmonary hypertension: The
Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of
the European Society of Cardiology (ESC) and the European Respiratory
Society (ERS), endorsed by the International Society of Heart and Lung
Transplantation (ISHLT). Eur Heart J. 2009;30:2493–537.
4. Hoeper MM, Markevych I, Spiekerkoetter E, Welte T, Niedermeyer J. Goal-oriented
treatment and combination therapy for pulmonary arterial hypertension. Eur
Respir J. 2005;26(5):858–63.
5. Ghofrani HA, Wiedemann R, Rose F, Olschewski H, Schermuly RT,
Weissmann N, et al. Combination therapy with oral sildenafil and inhaled
iloprost for severe pulmonary hypertension. Ann Intern Med. 2002;136(7):
515–22.
6. Ghofrani HA, Rose F, Schermuly RT, Olschewski H, Wiedemann R, Kreckel A, et al.
Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe
pulmonary arterial hypertension. J Am Coll Cardiol. 2003;42(1):158–64.
7. He B, Zhang F, Li X, Tang C, Lin G, Du J, et al. Meta-analysis of randomized
controlled trials on treatment of pulmonary arterial hypertension. Circ J.
2010;74(7):1458–64.
8. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke
JP. The Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) statement: guidelines for reporting observational
studies. Lancet. 2007;370(9596):1453–7.
9. Hoeper MM, Taha N, Bekjarova A, Gatzke R, Spiekerkoetter E. Bosentan
treatment in patients with primary pulmonary hypertension receiving
nonparenteral prostanoids. Eur Respir J. 2003;22(2):330–4.
10. Humbert M, Barst RJ, Robbins IM, Channick RN, Galie N, Boonstra A, et al.
Combination of bosentan with epoprostenol in pulmonary arterial
hypertension: BREATHE-2. Eur Respir J. 2004;24(3):353–9.
11. McLaughlin VV, Oudiz RJ, Frost A, Tapson VF, Murali S, Channick RN, et al.
Randomized study of adding inhaled iloprost to existing bosentan in pulmonary
arterial hypertension. Am J Respir Crit Care Med. 2006;174(11):1257–63.
12. Seyfarth HJ, Pankau H, Hammerschmidt S, Schauer J, Wirtz H, Winkler J.
Bosentan improves exercise tolerance and Tei index in patients with
pulmonary hypertension and prostanoid therapy. Chest. 2005;128(2):709–13.
13. Mathai SC, Girgis RE, Fisher MR, Champion HC, Housten-Harris T, Zaiman A,
et al. Addition of sildenafil to bosentan monotherapy in pulmonary arterial
hypertension. Eur Respir J. 2007;29(3):469–75.
14. Hoeper MM, Faulenbach C, Golpon H, Winkler J, Welte T, Niedermeyer J.
Combination therapy with bosentan and sildenafil in idiopathic pulmonary
arterial hypertension. Eur Respir J. 2004;24(6):1007–10.
15. Gomberg-Maitland M, McLaughlin V, Gulati M, Rich S. Efficacy and safety of
sildenafil added to treprostinil in pulmonary hypertension. Am J Cardiol.
2005;96(9):1334–6.
16. Ikeda D, Tsujino I, Ohira H, Itoh N, Kamigaki M, Ishimaru S, et al. Addition of oral
sildenafil to beraprost is a safe and effective therapeutic option for patients with
pulmonary hypertension. J Cardiovasc Pharmacol. 2005;45(4):286–9.
17. Kuhn KP, Wickersham NE, Robbins IM, Byrne DW. Acute effects of sildenafil
in patients with primary pulmonary hypertension receiving epoprostenol.
Exp Lung Res. 2004;30(2):135–45.
18. Stiebellehner L, Petkov V, Vonbank K, Funk G, Schenk P, Ziesche R, et al. Long-
term treatment with oral sildenafil in addition to continuous IV epoprostenol
in patients with pulmonary arterial hypertension. Chest. 2003;123(4):1293–5.
19. Wilkens H, Guth A, Konig J, Forestier N, Cremers B, Hennen B, et al. Effect of
inhaled iloprost plus oral sildenafil in patients with primary pulmonary
hypertension. Circulation. 2001;104(11):1218–22.
Gall et al. BMC Pulmonary Medicine  (2016) 16:5 Page 8 of 9
20. Benza RL, Seeger W, McLaughlin VV, Channick RN, Voswinckel R, Tapson VF,
et al. Long-term effects of inhaled treprostinil in patients with pulmonary
arterial hypertension: the Treprostinil Sodium Inhalation Used in the
Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-
label extension. J Heart Lung Transplant. 2011;30(12):1327–33.
21. Bai Y, Sun L, Hu S, Wei Y. Combination therapy in pulmonary arterial
hypertension: a meta-analysis. Cardiology. 2011;120(3):157–65.
22. Knebel SM, Elrick MM, Bowles EA, Zdanovec AK, Stephenson AH, Ellsworth
ML, et al. Synergistic effects of prostacyclin analogs and phosphodiesterase
inhibitors on cyclic adenosine 3’,5’ monophosphate accumulation and
adenosine 3’5’ triphosphate release from human erythrocytes. Exp Biol Med
(Maywood). 2013;238(9):1069–74.
23. Simonneau G, Rubin LJ, Galie N, Barst RJ, Fleming TR, Frost AE, et al.
Addition of sildenafil to long-term intravenous epoprostenol therapy in
patients with pulmonary arterial hypertension: a randomized trial. Ann
Intern Med. 2008;149(8):521–30.
24. Lopez-Meseguer M, Berastegui C, Monforte V, Bravo C, Domingo E, Roman
A. Inhaled iloprost plus oral sildenafil in patients with severe pulmonary
arterial hypertension delays the need for lung transplantation. Transplant
Proc. 2013;45(6):2347–50.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Gall et al. BMC Pulmonary Medicine  (2016) 16:5 Page 9 of 9
